Litcius/Paper detail

Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial

Armin Ghobadi, Veronika Bachanová, Krish Patel, Jae H. Park, Ian W. Flinn, Peter A. Riedell, Carlos Bachier, Catherine Diefenbach, Carol Wong, Cara Bickers, Lilly Wong, Deepa Patel, Jode Goodridge, Matthew Denholt, Bahram Valamehr, Rebecca Elstrom, Paolo Strati

2025The Lancet113 citationsDOIOpen Access PDF

Topics & Concepts

MedicineRituximabRegimenCytokine release syndromeFludarabineChimeric antigen receptorTolerabilityPharmacologyInternal medicineLymphomaCyclophosphamideOncologyAdverse effectImmunologyChemotherapyImmunotherapyCancerCAR-T cell therapy researchImmune Cell Function and InteractionPluripotent Stem Cells Research
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial | Litcius